Phase Ib Study of Magrolimab Plus Azacitidine in Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia

May 29-31, 2020; Online at
Combined with azacytidine, the anti-CD47 antibody magrolimab was well tolerated and associated with promising activity in untreated patients with MDS and AML.
Format: Microsoft PowerPoint (.ppt)
File Size: 235 KB
Released: June 5, 2020


Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie Inc.
Bristol-Myers Squibb
Karyopharm Therapeutics

Related Content

Multidisciplinary commentary on optimal use of HER2-targeted treatment in early and metastatic breast cancer, from Clinical Care Options (CCO)

Aditya Bardia, MD, MPH Sara Hurvitz, MD, FACP Kristi Kay Orbaugh, MSN, NP, AOCNP Danielle Roman, PharmD, BCOP Released: May 10, 2022

Two expert thoracic oncologists discuss novel anti-TIGIT immunotherapies for treatment of NSCLC, from Clinical Care Options (CCO)

person default Ani Balmanoukian, MD person default Jyoti D. Patel, MD Released: May 3, 2022

On-demand webcast on CAR T-cells for patients with hematologic malignancies, from Clinical Care Options (CCO)

Craig Freyer, PharmD, BCOP Andrew Lin, PharmD, BCOP Pharmacists: 1.0 contact hour (0.1 CEUs) Released: April 28, 2022 Expired: April 27, 2023

Diwakar Davar, MD, and Jyoti D. Patel, MD, discuss the role of TIGIT and emerging therapies for targeting TIGIT, including current trial data, from Clinical Care Options (CCO)

person default Diwakar Davar, MD person default Jyoti D. Patel, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: April 27, 2022 Expired: April 26, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings